[go: up one dir, main page]

WO2008101239A1 - Compositions et procédés d'apaisement de troubles de la peau - Google Patents

Compositions et procédés d'apaisement de troubles de la peau Download PDF

Info

Publication number
WO2008101239A1
WO2008101239A1 PCT/US2008/054242 US2008054242W WO2008101239A1 WO 2008101239 A1 WO2008101239 A1 WO 2008101239A1 US 2008054242 W US2008054242 W US 2008054242W WO 2008101239 A1 WO2008101239 A1 WO 2008101239A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
disorder
fco
coconut oil
person
Prior art date
Application number
PCT/US2008/054242
Other languages
English (en)
Inventor
Betty Bellman
Original Assignee
Betty Bellman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/739,303 external-priority patent/US7717329B1/en
Application filed by Betty Bellman filed Critical Betty Bellman
Publication of WO2008101239A1 publication Critical patent/WO2008101239A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the disclosure relates generally to the field of skin care and alleviation of skin disorders.
  • Numerous skin disorders are known in the art, including atopic dermatitis, eczema, and dry skin, for example. Such disorders include those associated with dryness, loss of suppleness, itching, redness, cracking, flaking, and other common symptoms.
  • the invention relates to a method of alleviating a skin disorder in a person.
  • the method comprises applying fractionated coconut oil to at least a portion of the skin affected by the disorder.
  • the invention also relates to a method of inhibiting development of a skin disorder in a portion of the skin of a person.
  • This method comprises applying fractionated coconut oil to the portion in an amount sufficient to inhibit development of the disorder.
  • the disclosure relates to compositions and methods for alleviating skin disorders.
  • a skin disorder including atopic dermatitis, eczema, and dry skin, for example
  • application of fractionated coconut oil can prevent or inhibit the onset or severity of a skin disorder.
  • coconut oil is an oil extracted from the flesh of coconuts (e.g., coconuts of the species Cocos nucifera). It is a fat consisting of about 90% saturated fat. The oil contains mostly medium chain triglycerides, with about 87% saturated fatty acids, 6% monounsaturated fatty acids, and 2% polyunsaturated fatty acids. Coconut oil is known to contain several different saturated fatty acids. Nonetheless, about 45% of the saturated fatty acids are lauric acid, about 17% are myristic acid, and about 8% are palmitic acid. Monounsaturated fatty acids in coconut oil include primarily oleic acid, and the only polyunsaturated fatty acid generally present is linoleic acid.
  • Fractionated coconut oil is a fraction of the whole oil, in which most of the long- chain triglycerides are removed, leaving only saturated fats in the fractionated oil.
  • Fractionated coconut oil is sometimes referred to as "caprylic/capric triglyceride” or MCT oil because mostly the medium-chain triglycerides (caprylic and capric acid) are left in the oil.
  • FCO tends to lack the scent normally associated with coconut oil (or, more properly, with the portions of coconut oil not present in FCO). FCO has a very light and clean skin feel, applies smoothly, and tends to dry more quickly than other known skin oils.
  • a person afflicted with a skin disorder applies FCO to their skin, or to the portions of the skin affected by the disorder.
  • the amount of FCO is not critical, and can be about as much oil as will ordinarily adhere to the skin at room temperature. Because FCO is not believed to exhibit any significant toxicity, it can be applied to the skin liberally, generally as often as desired by the person. In general, the FCO should be applied to the skin not less frequently than about once every few days, and not more frequently than every two hours, and preferably once or twice per day. This higher frequency is not dictated by safety or operability. Nonetheless, it is recognized that, at high application frequencies, the efficacy of the composition may be little or no greater than at lower application frequencies.
  • FCO can be applied to the skin of a healty person (i.e., a person who is not afflicted with a skin disorder, or who is not recognized as being afflicted with a skin disorder) in order to prevent or delay the onset of the skin disorder, or to reduce the severity of the skin disorder should it occur.
  • a healty person i.e., a person who is not afflicted with a skin disorder, or who is not recognized as being afflicted with a skin disorder
  • the amount of FCO applied to the skin should be an amount sufficient to create a film of the oil on the skin, and not more than the amount that will adhere to the skin without dripping. This amount is believed to be approximately 5 milliliters per square meter of skin surface, although this amount is merely an estimate. Approximately 0.5 millliliters of FCO is sufficient to apply to front half of the thigh of an adult woman, for example.
  • the form in which the FCO is applied is not critical. Generally, because FCO is a liquid at room temperature, it can be applied as a fluid. By way of example, the FCO can be applied using a spray device or atomizer, by pouring or rubbing it onto the skin, by daubing it onto the skin using a sponge or brash, by rolling it on using a TmIl point pen' or 'roll-on deodorant' type container, or otherwise. Although the FCO is preferably applied as a liquid, it can be incorporated into a variety of bases or vehicles, such as creams, lotions, mousses, foams, pastes, or the like. Similarly, if applied below its congealing temperature, FCO can be applied as a solid, for example by rubbing or wiping the solid FCO onto the skin.
  • ⁇ disorders that can be alleviated or prevented by topical application of FCO to the skin include atopic dermatitis, eczema, and dry skin. This list of disorders is not limiting. Other skin disorders can be similarly treated.
  • Cromolyn compounds e.g., cromolyn sodium
  • Cromolyn compounds are known mast cell stabilizing agents that can prevent release of histamine from mast cells.
  • the composition can have the effects described herein for FCO and can also alleviate or prevent inflammation, itching, and irritation and decrease the severity of the same.
  • cromolyn sodium can, for example, be included in an amount of about 1% to about 10% by weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne la découverte de l'efficacité de l'huile de noix de coco fractionnée pour apaiser des troubles de la peau existants, lorsqu'elle est appliquée par voie topique sur la peau d'une personne atteinte d'un tel trouble. L'invention concerne également la découverte de l'utilisation possible de l'huile de noix de coco fractionnée pour prévenir ou empêcher l'apparition d'un trouble de la peau, ou pour réduire l'importance d'un trouble de la peau, lorsqu'elle est administrée de manière prophylactique sur la peau d'une personne.
PCT/US2008/054242 2007-02-16 2008-02-19 Compositions et procédés d'apaisement de troubles de la peau WO2008101239A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89044707P 2007-02-16 2007-02-16
US60/890,447 2007-02-16
US11/739,303 2007-04-24
US11/739,303 US7717329B1 (en) 2006-02-16 2007-04-24 Check carrier

Publications (1)

Publication Number Publication Date
WO2008101239A1 true WO2008101239A1 (fr) 2008-08-21

Family

ID=39690559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/054242 WO2008101239A1 (fr) 2007-02-16 2008-02-19 Compositions et procédés d'apaisement de troubles de la peau

Country Status (1)

Country Link
WO (1) WO2008101239A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011237A1 (fr) * 1997-09-01 1999-03-11 The Boots Company Plc Composition dermatologique
KR20000046633A (ko) * 1998-12-31 2000-07-25 성재갑 아토피성 피부염 치유용 조성물
WO2002047642A1 (fr) * 2000-12-15 2002-06-20 Schering Ag Preparations de soin pour la peau, hypoallergeniques et non irritantes
WO2005067691A2 (fr) * 2004-01-07 2005-07-28 E-L Management Corporation Composition cosmetique contenant une proteine et un inhibiteur d'enzyme
KR20070000599A (ko) * 2005-06-28 2007-01-03 주식회사 엘지생활건강 피부 장벽 기능 개선용 피부 외용제 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011237A1 (fr) * 1997-09-01 1999-03-11 The Boots Company Plc Composition dermatologique
KR20000046633A (ko) * 1998-12-31 2000-07-25 성재갑 아토피성 피부염 치유용 조성물
WO2002047642A1 (fr) * 2000-12-15 2002-06-20 Schering Ag Preparations de soin pour la peau, hypoallergeniques et non irritantes
WO2005067691A2 (fr) * 2004-01-07 2005-07-28 E-L Management Corporation Composition cosmetique contenant une proteine et un inhibiteur d'enzyme
KR20070000599A (ko) * 2005-06-28 2007-01-03 주식회사 엘지생활건강 피부 장벽 기능 개선용 피부 외용제 조성물

Similar Documents

Publication Publication Date Title
US5945109A (en) Cosmetic or cosmetic product for firming and smoothing the skin, in particular in the case of cellulite
CA2919258C (fr) Formulations pour la reparation epidermique
US5705170A (en) Herbal cellulite treatments
KR101420599B1 (ko) 항여드름제를 함유하는 조성물 및 이의 용도
US20190021961A1 (en) Water-in-oil emulsion
CN107753332B (zh) 一种多效油膏
US7488500B2 (en) Compositions and methods for alleviating skin disorders
CN108852912A (zh) 一种保湿润肤乳液及其制备方法
EP1603517B1 (fr) Produit de soin pour la peau contenant des acides gras de resine liquide et des huiles vegetales pour peau seche et desquamee et traitement du psoriasis, de la dermatite et des eczemas
US9011943B2 (en) Compositions and methods for alleviating skin disorders
PL190023B1 (pl) Zastosowanie mieszaniny diolu i alfa-hydroksykwasu do wytwarzani leku do leczenia hiperkeratozowychchorób skóry
JPH09241146A (ja) 皮膚外用剤
RU2218324C2 (ru) Композиция для ухода за кожей, содержащая липидную смесь
US7758901B2 (en) Compositions and methods for alleviating skin disorders
AU2019299943A1 (en) Anti-allergenic ocular compositions and eyelid cleansing wipes
DE202006019184U1 (de) Feuchtigkeitsspendendes Sanddorn-Hautpflegegel
WO2009084032A2 (fr) Formulation topique hydrophobe stable à base de plantes
WO2008101239A1 (fr) Compositions et procédés d'apaisement de troubles de la peau
DE60107809T2 (de) Pflanzenöl für die herstellung einer hemmender zusammensetzung der 5--alpha reduktase
JP3047179B1 (ja) 皮膚化粧料
CN109475138B (zh) 多功能结构化缩水甘油/非缩水甘油基质
WO2010111374A2 (fr) Compositions et procédés pour soulager des affections cutanées
CN107822929B (zh) 一种有效缓解瘙痒的头皮护理精油
KR20050048287A (ko) 아토피성 피부염을 개선을 위한 화장품 조성물
JP3932209B2 (ja) 皮膚外用剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08730111

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08730111

Country of ref document: EP

Kind code of ref document: A1